MedTrace Logo

Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens

NCT00204516 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2013-01-16

No results posted yet for this study

Summary

The purpose of the vaccination protocol is to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen.

Conditions

  • Malignant Melanoma

Interventions

BIOLOGICAL

mRNA coding for melanoma associated antigens

mRNA vaccine s.c. applied weekly

DRUG

GM-CSF

Given s.c. as adjuvant drug one day after vaccine

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Claus Garbe, Prof. Dr. · University of Tuebingen, Department of Dermatology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2011-08-31
Completion
2012-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00204516 on ClinicalTrials.gov